Takako Shimizu
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Physiologically Based Pharmacokinetic Modeling of Valemetostat to Inform Dose Recommendations When Coadministered With CYP3A/P-gp Modulators.
Journal: Clinical and translational science
Published: March 20, 2025
Effect of Rifampicin on the Pharmacokinetics of Valemetostat and Its Primary Metabolite: A Phase 1 Study in Healthy Participants.
Journal: Clinical and translational science
Published: March 20, 2025
New Horizon in Clinical Development Strategy in Japan Based on New Guideline on Japanese Phase 1 Studies Prior to Multi-Regional Clinical Trials.
Journal: Clinical and translational science
Published: February 12, 2025
Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open-Label, Phase I Study.
Journal: Clinical pharmacology in drug development
Published: January 17, 2025
Pharmacokinetics, metabolism, and excretion of [14C]-valemetostat in healthy male participants, and in vitro plasma protein binding.
Journal: Cancer chemotherapy and pharmacology
Published: November 01, 2024
Population pharmacokinetics of total and unbound valemetostat and platelet dynamics in healthy volunteers and patients with non-Hodgkin lymphoma.
Journal: CPT: pharmacometrics & systems pharmacology
Published: March 04, 2024
Bayesian sparse regression for exposure-response analyses of efficacy and safety endpoints to justify the clinical dose of valemetostat for adult T-cell leukemia/lymphoma.
Journal: CPT: pharmacometrics & systems pharmacology
Published: March 04, 2024
Physiologically Based Pharmacokinetic Absorption Model for Pexidartinib to Evaluate the Impact of Meal Contents and Intake Timing on Drug Exposure.
Journal: Clinical pharmacology in drug development
Published: September 08, 2023
Exposure-response analysis of the efficacy and safety of esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with or without diabetic kidney disease.
Journal: Drug metabolism and pharmacokinetics
Published: July 07, 2023
Safety, Tolerability, and Pharmacokinetics of Valemetostat Tablets and the Effect of Food on Valemetostat Pharmacokinetics in Healthy Subjects: Two Phase 1 Studies.
Journal: Clinical pharmacology in drug development
Published: May 19, 2023
Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open-label, phase I study in healthy subjects.
Journal: Clinical and translational science
Published: May 05, 2023
Population pharmacokinetics of esaxerenone, a novel non-steroidal mineralocorticoid receptor blocker, in patients with essential hypertension, patients with diabetic nephropathy, and healthy volunteers.
Journal: Drug metabolism and pharmacokinetics
Published: February 06, 2023
Last Updated: 09/26/2026